This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2020
ASCO GU 2020
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2020 Prostate Cancer
Viewing 1-20 of 92 articles
Randomized phase 2 study of sipuleucel-T (Sip-T) with or without radium-233 (Ra-223) in men with bone metastatic castration-resistant prostate cancer - Poster
ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: The PROfound Trial
ASCO GU 2020: A Phase II Study of Talazoparib in Men with DNA Damage Repair Mutations and Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2020: Assessment of Inherited DNA Repair Defects in African-American and Caucasian Men with Prostate Cancer
ASCO GU 2020: Phase Ib Study of Niraparib plus Androgen Receptor-Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2020: Phase II Study of Cabazitaxel plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2020: Safety and Effectiveness of Radium-223 Dichloride in Patients with mCRPC in Real-World Setting: A Japanese Post-Marketing Study
ASCO GU 2020: Treatment of Chemotherapy-Naïve mCRPC Using Abiraterone Acetate with or without Cabazitaxel
ASCO GU 2020: Preliminary Outcomes of A Prospective Observational Study of Combinatorial Abiraterone Acetate/Enzalutamide and Radical Radiotherapy in Nonmetastatic Node-Positive Prostate Cancer
ASCO GU 2020: Prognostic Factors that Affect Survival Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223
ASCO GU 2020: A Comparison of Sipuleucel-T Product Parameters from Two Phase III Studies: PROVENT in Active Surveillance Prostate Cancer and IMPACT in Metastatic Castrate-Resistant Prostate Cancer
ASCO GU 2020: The Association of Humoral Antigen Spread with Cytotoxic T Lymphocyte Activity after Sipuleucel-T Treatment in Two Phase II Clinical Studies: STAMP and STRIDE
ASCO GU 2020: Assessing Different Sequencing Regimens of Atezolizumab and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
ASCO GU 2020: Correlative Measures of Tumor Response in the Phase II GALAHAD Study
ASCO GU 2020: The Use of Novel Tools in the Active Surveillance
ASCO GU 2020: Overall Survival in Men with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Receiving Bicalutamide Followed by Enzalutamide or Abiraterone
ASCO GU 2020: Implementation of Novel Tools in the Active Surveillance Pathway
ASCO GU 2020: New Standards in First-Line Therapy for Advanced Disease
ASCO GU 2020: Real-World Analysis of Prostate-Specific Antigen Outcomes Among Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide
ASCO GU 2020: Meet the Regulators: History of Metastasis-Free Survival and Drug Development in Nonmetastatic Castrate-Resistant Prostate Cancer
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free